Unique ID issued by UMIN | UMIN000024284 |
---|---|
Receipt number | R000027975 |
Scientific Title | A non-inferiority trial about the efficacy, safety, and effect on QOL of weekly-DPP-4 inhibitor omarigliptin by the comparison with once-daily-DPP-4 inhibitor linagliptin in maintenance hemodialysis patients with type 2 diabetes. |
Date of disclosure of the study information | 2016/10/11 |
Last modified on | 2019/03/31 09:48:45 |
A non-inferiority trial about the efficacy, safety, and effect on QOL of weekly-DPP-4 inhibitor omarigliptin by the comparison with once-daily-DPP-4 inhibitor linagliptin in maintenance hemodialysis patients with type 2 diabetes.
A non-inferiority trial about the efficacy, safety, and effect on QOL of weekly-DPP-4 inhibitor omarigliptin by the comparison with once-daily-DPP-4 inhibitor linagliptin in maintenance hemodialysis patients with type 2 diabetes.
A non-inferiority trial about the efficacy, safety, and effect on QOL of weekly-DPP-4 inhibitor omarigliptin by the comparison with once-daily-DPP-4 inhibitor linagliptin in maintenance hemodialysis patients with type 2 diabetes.
A non-inferiority trial about the efficacy, safety, and effect on QOL of weekly-DPP-4 inhibitor omarigliptin by the comparison with once-daily-DPP-4 inhibitor linagliptin in maintenance hemodialysis patients with type 2 diabetes.
Japan |
End-stage renal disease caused by type 2 diabetes
Endocrinology and Metabolism | Nephrology |
Others
NO
To evaluate the efficacy, safety and effect on QOL of weekly-DPP-4 inhibitor omarigliptin by comparing with once-daily-DPP-4 inhibitor linagliptin in maintenance hemodialysis patients with type 2 diabetes.
Safety,Efficacy
Exploratory
Pragmatic
Not applicable
The change in glycoalbumin (GA) and HbA1c.
Secondary outcomes
1. The change in the scores of Development and Psychometric Validation of the Diabetes Therapy-Related QOL (DTR-QOL) Questionnaire.
2. The change in body composition evaluated by using InBody.
3. The change of blood glucose, GLP-1, GIP, and glucagon during hemodialysis treatment.
4. The change in the interdialytic weight gain rate.
Safety outcomes
1. Frequency of serious adverse events associated with the use of omarigliptin.
2. Frequency of hypoglycemia events associated with the use of omarigliptin.
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
Numbered container method
2
Treatment
Medicine |
Once-weekly oral administration of omarigliptin (12.5mg) for 6 months.
Once-daily oral administration of linagliptin (5mg) for 6 months.
20 | years-old | <= |
Not applicable |
Male and Female
1. Those undergoing maintenance hemodialysis for more than 6 months.
2. Those aged 20 or over, with type 2 diabetes treated with DPP-4 inhibitors for more than 3 months.
3. Those who have given written informed consent on the use of their clinical data for this trial.
1. Those undergoing maintenance hemodialysis for more than 6 months.
2. Those aged 20 or over, with type 2 diabetes treated with DPP-4 inhibitors for more than 3 months.
3. Those who have given written informed consent on the use of their clinical data for this trial.
1. Those who have been treated with GLP-1 receptor agonists.
2. Those with hypersensitivity to DPP-4 inhibitors or GLP-1 receptor agonists.
3. Those with serious diabetic ketosis, coma, or pre-coma.
4. Those with severe active infection, serious trauma, or in the perioperative period.
5. Those with severe heart or liver dysfunction
6. Those with problems shown as below:
1) Pituitary gland or adrenal gland dysfunction
2) In the status of impaired nutrition, starvation, irregular or insufficient dietary intake, or hyposthenia.
3) Excessive muscular exercise
4) Heavy alcohol drinkers.
7. Those who are pregnant or beast-feeding, or those who might be pregnant
8. Those with uncontrolled hyper glycaemia (GA >=27% or HbA1c >=9%), on their current treatment with the oral medicine.
9. Those who are considered not eligible for this trial by attending doctors due to any medical reasons.
30
1st name | Akihiko |
Middle name | |
Last name | Saito |
Niigata University Graduate School of Medical and Dental Sciences
Department of Applied Molecular Medicine
951-8520
1-757 Asahimachi-dori, Chuo-ku, Niigata-shi
025-227-0915
akisaito@med.niigata-u.ac.jp
1st name | Michihiro |
Middle name | |
Last name | Hosojima |
Niigata University Graduate School of Medical and Dental Sciences
Department of Clinical Nutrition Science
951-8520
1-757 Asahimachi-dori, Chuo-ku, Niigata-shi
025-368-9312
hoso9582@med.niigata-u.ac.jp
Niigata University Graduate School of Medical and Dental Sciences
Department of Applied Molecular Medicine
None
Self funding
Shinrakuen Hospital
Nagaoka Red Cross Hospital
Nagaoka Chuo General Hospital
Sado General Hospital
Kido Hospital
Niigata Saiseikai Sanjo Hospital
Koyo Medical Clinic
Maihira Clinic
University of Niigata Prefecture
Gunma University
The institutional review boards of Niigata University
1-757 Asahimachi-dori, Chuo-ku, Niigata-shi
025-227-2006
shomu@med.niigata-u.ac.jp
NO
新潟大学医歯学総合病院(新潟県)、信楽園病院(新潟県)、長岡赤十字病院(新潟県)、長岡中央総合病院(新潟県)、佐渡総合病院(新潟県)、木戸病院(新潟県)、
新潟県済生会三条病院(新潟県)、向陽メディカルクリニック(新潟県)、舞平クリニック(新潟県)
2016 | Year | 10 | Month | 11 | Day |
Unpublished
33
Completed
2016 | Year | 09 | Month | 02 | Day |
2016 | Year | 08 | Month | 22 | Day |
2016 | Year | 10 | Month | 11 | Day |
2019 | Year | 03 | Month | 10 | Day |
2019 | Year | 03 | Month | 10 | Day |
2019 | Year | 03 | Month | 23 | Day |
2019 | Year | 03 | Month | 28 | Day |
2016 | Year | 10 | Month | 04 | Day |
2019 | Year | 03 | Month | 31 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027975
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |